Selective small-molecule inhibition of an RNA structural element
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Riboswitches are non-coding RNA structures located in messenger RNAs that bind endogenous ligands, such as a specific metabolite or ion, to regulate gene expression. As such, riboswitches serve as a novel, yet largely unexploited, class of emerging drug targets. Demonstrating this potential, however, has proven difficult and is restricted to structurally similar antimetabolites and semi-synthetic analogues of their cognate ligand, thus greatly restricting the chemical space and selectivity sought for such inhibitors. Here we report the discovery and characterization of ribocil, a highly selective chemical modulator of bacterial riboflavin riboswitches, which was identified in a phenotypic screen and acts as a structurally distinct synthetic mimic of the natural ligand, flavin mononucleotide, to repress riboswitch-mediated ribB gene expression and inhibit bacterial cell growth. Our findings indicate that non-coding RNA structural elements may be more broadly targeted by synthetic small molecules than previously expected.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ribocil binding inhibits translation of ribB transcript in E. coli, inducing cell death by riboflavin starvation.”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [123]
In the citing paper
“a high throughput screening of small molecules recently identified an inhibitor of riboflavin synthesis, called “ribocil”, that targets a regulatory non-coding region (i.e. riboswitch) in the mRNA of a synthase involved in the pathway, ribB [123].”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [123]
In the citing paper
“ribocil administration, although only at high concentrations, significantly reduced bacterial burden in a mouse model of systemic infection with E. coli”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [123]
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products
Datsenko, K. A., & Wanner, B. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120163297 · Cited by 14,782
Construction of Escherichia coli K‐12 in‐frame, single‐gene knockout mutants: the Keio collection
Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., Tomita, M., Wanner, B. L., & Mori, H. (2006) · Molecular Systems Biology · doi:10.1038/msb4100050 · Cited by 7,858
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Landscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187
Self-citationBad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,697
Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis
Winzeler, E. A., Shoemaker, D. D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J. D., Bussey, H., et al. (1999) · Science · doi:10.1126/science.285.5429.901 · Cited by 3,953
Research works printed but not linked: 2
- Kodali, S. et al. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J. Biol. Chem. 280, 1669–1677 (2005) · DOI
- Bricogne, G. et al. BUSTER version 2.11.5 http://www.globalphasing.com (2014)
Cited by
Items 101–200 of 406
Kofoed, E. M., Yan, D., Katakam, A. K., Reichelt, M., Lin, B., Kim, J., Park, S., Date, S. V., Monk, I. R., Xu, M. J., et al. (2016) · Journal of Bacteriology · doi:10.1128/jb.00051-16 · Cited by 57
A cross-linking approach to map small molecule-RNA binding sites in cells
Velagapudi, S. P., Li, Y., & Disney, M. D. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.001 · Cited by 52
Contemporary Progress and Opportunities in RNA-Targeted Drug Discovery
Garner, A. L. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00020 · Cited by 55
Targeting RNA structures in diseases with small molecules
Shao, Y., & Zhang, Q. C. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200011 · Cited by 54
A chemical probe based on the PreQ1 metabolite enables transcriptome-wide mapping of binding sites
Balaratnam, S., Rhodes, C. A., Bume, D. D., Connelly, C. M., Lai, C. C., Kelley, J. A., Yazdani, K., Homan, P., Incarnato, D., Numata, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25973-x · Cited by 54
Tong, Y., Zhang, P., Yang, X., Liu, X., Zhang, J., Grudniewska, M., Jung, I., Abegg, D., Liu, J., Childs‐Disney, J. L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306682120 · Cited by 53
“Nature has evolved processes that allow small molecules to con-trol the structural switching of bacterial RNAs to regulate production of metabolites, and these riboswitches are the targets of antibacterials (58, 59).”
BackgroundLong noncoding RNA loss in immune suppression in cancer
Hu, Q., Egranov, S. D., Lin, C., & Yang, L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107591 · Cited by 46
Chavali, S. S., Bonn, R. B., & Wedekind, J. E. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006860 · Cited by 52
“Gua62 (J4-5) stacks against the phenyl group of the inhibitor, reminiscent of the 2-methylaminopyrimidine moiety of ribocil—the synthetic FMN analogue discovered by Merck (21).”
BackgroundInfluentialHua, B., Jones, C. P., Mitra, J., Murray, P. J., Rosenthal, R., Ferré-D’Amaré, A. R., & Ha, T. (2020) · Nature Communications · doi:10.1038/s41467-020-18283-1 · Cited by 45
Discovery of small molecules that target a tertiary-structured RNA
Menichelli, E., Lam, B. J., Wang, Y., Wang, V. S., Shaffer, J., Tjhung, K. F., Bursulaya, B. D., Nguyen, T. N., Vo, T., Alper, P. B., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213117119 · Cited by 49
“A phenotypic screen of ~57,000 compounds was carried out to identify compounds that suppress bacterial growth in the absence of externally supplied riboflavin (17).”
RNA-Binding Small Molecules in Drug Discovery and Delivery: An Overview from Fundamentals
Chen, S., Mao, Q., Cheng, H. B., & Tai, W. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01330 · Cited by 49
Functional RNA structures throughout the Hepatitis C Virus genome
Adams, R. L., Pirakitikulr, N., & Pyle, A. M. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.04.007 · Cited by 44
Warrier, I., Ram-Mohan, N., Zhu, Z., Hazery, A., Echlin, H., Rosch, J. W., Meyer, M. M., & van Opijnen, T. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007461 · Cited by 46
Compound Uptake into E. coli Can Be Facilitated by N -Alkyl Guanidiniums and Pyridiniums
Perlmutter, S. J., Geddes, E. J., Drown, B., Motika, S. E., Lee, M., & Hergenrother, P. J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00715 · Cited by 44
Khan, M. A., Göpel, Y., Milewski, S., & Görke, B. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00908 · Cited by 44
“The latter strain is unable to synthesize bacilysin due to inactivation of gene ywfE (bacD) encoding alanine–anticapsin ligase (Inaoka et al., 2009).”
BackgroundMethodInfluentialValeur, E., & Jimonet, P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00378 · Cited by 43
Riboswitches as therapeutic targets: promise of a new era of antibiotics
Ellinger, E., Chauvier, A., Romero, R. A., Liu, Y., Ray, S., & Walter, N. G. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2230363 · Cited by 43
“riboswitch but quickly triggers RNA mutations, leading the company to abandon this drug [45] (Figure 4(d)).”
BackgroundIdentification of the Key Enzyme of Roseoflavin Biosynthesis
Schwarz, J., Konjik, V., Jankowitsch, F., Sandhoff, R., & Mack, M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201600581 · Cited by 41
Rizvi, N. F., & Nickbarg, E. B. (2019) · Methods · doi:10.1016/j.ymeth.2019.04.024 · Cited by 43
Fandozzi, C. M., Evans, C. A., Wilson, A., Su, D., Anderson, M., Clausen, V. A., Dillen, L., Garofolo, F., Holliman, C., Nickbarg, E. B., et al. (2019) · Bioanalysis · doi:10.4155/bio-2019-0260 · Cited by 40
Expanding the DNA-encoded library toolbox: identifying small molecules targeting RNA
Chen, Q., Li, Y., Lin, C., Chen, L., Luo, H., Xia, S., Liu, C., Cheng, X., Liu, C., Li, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac173 · Cited by 40
“Ribocil-C is a reported small molecule specifically binds FMN Riboswitch and exhibits anti-bacterial growth effect (24), we further investigated DEL selection for this target in order to demonstrate the ability of the optimized selection strategy and find active compounds.”
InfluentialChoi, S. J., & Ban, C. (2016) · Scientific Reports · doi:10.1038/srep34998 · Cited by 47
Belashov, I. A., Crawford, D. W., Cavender, C. E., Dai, P., Beardslee, P. C., Mathews, D. H., Pentelute, B. L., McNaughton, B. R., & Wedekind, J. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky529 · Cited by 44
Identifying small-molecules binding sites in RNA conformational ensembles with SHAMAN
Panei, F. P., Gkeka, P., & Bonomi, M. (2024) · Nature Communications · doi:10.1038/s41467-024-49638-7 · Cited by 44
“The paper highlights differences in results obtained from simulations initiated with apo and holo conformations, which raises concerns regarding sampling completeness.”
Pavlova, N., & Prof. Robert Penchovsky, D. R. N. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1618274 · Cited by 39
“It represses the gene expression of the ribB gene and inhibits the bacterial cell [39].”
BackgroundA Riboswitch-Driven Era of New Antibacterials
Γιαρίμογλου, Ν., Kouvela, A., Maniatis, A., Papakyriakou, A., Zhang, J., Stamatopoulou, V., & Stathopoulos, C. (2022) · Antibiotics · doi:10.3390/antibiotics11091243 · Cited by 43
“A synthetic compound with antimicrobial activity, ribocil, which is able to target the FMN riboswitch, has been identified using a phenotypic screen [58].”
BackgroundMethodCui, K., Wu, H., Fan, J., Zhang, L., Li, H., Guo, H., Yang, R., & Li, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012106 · Cited by 37
“Small molecules alter the conformation of lncRNAs [19] or act as their inhibitors [20] to target and regulate their expression.”
BackgroundTackling Antimicrobial Resistance by Exploring New Mechanisms of Antibiotic Action
de Opitz, C. L. M., & Saß, P. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0048 · Cited by 37
Yan, L., Roux, A. L., Boyapelly, K., Lamontagne, A.-M., Archambault, M.-A., Picard‐Jean, F., Séguin, D. L., St-Pierre, É., Najmanovich, R., Fortier, L., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.079 · Cited by 36
Are outer-membrane targets the solution for MDR Gram-negative bacteria?
Walker, S. S., & Black, T. A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.027 · Cited by 36
Self-citationLorenz, D. A., Roest, S. V., Larsen, M. J., & Garner, A. L. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217717944 · Cited by 38
Chu, C.-C., Plangger, R., Kreutz, C., & Al‐Hashimi, H. M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz498 · Cited by 39
Schroeder, G. M., Dutta, D., Cavender, C. E., Jenkins, J. L., Pritchett, E. M., Baker, C. D., Ashton, J. M., Mathews, D. H., & Wedekind, J. E. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa546 · Cited by 35
Hierarchical mechanism of amino acid sensing by the T-box riboswitch
Suddala, K. C., Cabello‐Villegas, J., Michnicka, M., Marshall, C., Nikonowicz, E. P., & Walter, N. G. (2018) · Nature Communications · doi:10.1038/s41467-018-04305-6 · Cited by 36
Metabolic engineering of roseoflavin-overproducing microorganisms
Mora‐Lugo, R., Stegmüller, J., & Mack, M. (2019) · Microbial Cell Factories · doi:10.1186/s12934-019-1181-2 · Cited by 33
Cheng, L., White, E. N., Brandt, N. L., Yu, A. M., Chen, A. A., & Lucks, J. B. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac102 · Cited by 36
“We also anticipate this work to directly inform the design of synthetic riboswitch systems for a range of important synthetic biology applications (38,49–51) as well as the design and mechanistic understanding of RNA-targeting drugs (52).”
BackgroundAffinity-Based Profiling of the Flavin Mononucleotide Riboswitch
Crielaard, S., Maassen, R., Vosman, T., Rempkens, I., & Velema, W. A. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02685 · Cited by 35
RNet: a network strategy to predict RNA binding preferences
Liu, H., Jian, Y., Hou, J., Zeng, C., & Zhao, Y. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad482 · Cited by 32
RNA-based mechanisms of virulence control in Enterobacteriaceae
Heroven, A. K., Nuss, A. M., & Dersch, P. (2016) · RNA Biology · doi:10.1080/15476286.2016.1201617 · Cited by 34
“aptamer-based riboswitch blocker have recently been identified.(144,146) A pitfall in this approach is that many”
BackgroundRecognition of single-stranded nucleic acids by small-molecule splicing modulators
Tang, Z., Akhter, S., Ramprasad, A., Wang, X., Reibarkh, M., Wang, J., Aryal, S., Thota, S. S., Zhao, J., Douglas, J. T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab602 · Cited by 36
NMR characterization of RNA small molecule interactions
Thompson, R. D., Baisden, J. T., & Zhang, Q. (2019) · Methods · doi:10.1016/j.ymeth.2019.05.015 · Cited by 35
“These efforts have also led to recent successes on identifying bioactive small-molecule inhibitors that target structured FMN riboswitch [149] and self-splicing group II intron [150], demonstrating that highly structured RNAs can indeed be outstanding targets for drug discovery.”
Davodabadi, F., Far, B. F., Sargazi, S., Sajjadi, S. F., Fathi‐karkan, S., Mirinejad, S., Ghotekar, S. K., Sargazi, S., & Rahman, M. M. (2024) · ChemMedChem · doi:10.1002/cmdc.202300528 · Cited by 33
RNA–Small-Molecule Interaction: Challenging the “Undruggable” Tag
Kaur, J., Sharma, A., Mundlia, P., Sood, V., Pandey, A., Singh, G., & Barnwal, R. P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01354 · Cited by 35
Bleomycin Can Cleave an Oncogenic Noncoding RNA
Angelbello, A. J., & Disney, M. D. (2017) · ChemBioChem · doi:10.1002/cbic.201700581 · Cited by 32
Characterization of clinically used oral antiseptics as quadruplex-binding ligands
Calabrese, D. R., Zlotkowski, K., Alden, S. L., Hewitt, W. M., Connelly, C. M., Wilson, R. M., Gaikwad, S. M., Chen, L., Guha, R., Thomas, C. J., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky084 · Cited by 32
Methods to identify and optimize small molecules interacting with RNA (SMIRNAs)
Ursu, A., Vézina‐Dawod, S., & Disney, M. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.019 · Cited by 33
“The identification of RNAs as key pathological agents in many diseases and the serendipitous discovery that small molecules identified from phenotypic screens act on the RNA [1] or premRNA and the RNA/spliceosome interface [2,3] support the notion of targeting RNA for therapeutic benefit.”
BackgroundKallert, E., Fischer, T. R., Schneider, S., Grimm, M., Helm, M., & Kersten, C. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00751 · Cited by 33
Non-coding RNAs as antibiotic targets
Colameco, S., & Elliot, M. A. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.015 · Cited by 34
Structure‐Switching RNAs: From Gene Expression Regulation to Small Molecule Detection
Husser, C., Dentz, N., & Ryckelynck, M. (2021) · Small Structures · doi:10.1002/sstr.202000132 · Cited by 31
Morishita, E. C. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2134852 · Cited by 29
“…directed against already-known functional RNA motifs, such as HIV-1 transactivation response (TAR) [19], the flavin mononucleotide (FMN) riboswitch [20–22], the severe acute respiratory syndrome coronavirus frameshifting pseudoknot [23], viral internal ribosomal entry sites (IRES) [8,24], and…”
BackgroundMaria, J. P. S., Park, Y., Yang, L., Murgolo, N., Altman, M. D., Zuck, P. D., Adam, G., Chamberlin, C., Saradjian, P., Dandliker, P. J., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00468 · Cited by 30
Self-citationAntibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase
Walker, S. S., Labroli, M. A., Painter, R. E., Wiltsie, J., Sherborne, B. S., Murgolo, N., Sher, X., Mann, P. A., Zuck, P. D., Garlisi, C. G., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180965 · Cited by 32
Self-citationRNATACs: Multispecific small molecules targeting RNA by induced proximity
Song, Y., Cui, J., Zhu, J., Kim, B., Kuo, M.-L., & Potts, P. R. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.05.006 · Cited by 31
RLDOCK method for predicting RNA-small molecule binding modes
Jiang, Y., & Chen, S. (2021) · Methods · doi:10.1016/j.ymeth.2021.01.009 · Cited by 31
SILCS-RNA: Toward a Structure-Based Drug Design Approach for Targeting RNAs with Small Molecules
Kognole, A. A., Hazel, A. J., & MacKerell, A. D. (2022) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c00381 · Cited by 31
Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen
Prado, S., Beltrán, M., Coiras, M., Bedoya, L. M., Alcamı́, J., & Gallego, J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.007 · Cited by 28
Rode, A. B., Endoh, T., & Sugimoto, N. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201803052 · Cited by 29
Low-Molecular Weight Small Molecules Can Potently Bind RNA and Affect Oncogenic Pathways in Cells
Suresh, B. M., Akahori, Y., Taghavi, A., Crynen, G. C., Gibaut, Q. M. R., Li, Y., & Disney, M. D. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08770 · Cited by 29
Machine Learning Informs RNA‐Binding Chemical Space**
Yazdani, K., Jordan, D., Yang, M., Fullenkamp, C. R., Calabrese, D. R., Boer, R. E., Hilimire, T. A., Allen, T. E. H., Khan, R. T., & Schneekloth, J. S. (2022) · Angewandte Chemie · doi:10.1002/ange.202211358 · Cited by 26
Activation of the glmS Ribozyme Confers Bacterial Growth Inhibition
Schüller, A., Matzner, D., Weinberg, C. E., Wittmann, V., Schumacher, C., Unsleber, S., Brötz‐Oesterhelt, H., Mayer, C., Bierbaum, G., & Mayer, G. (2016) · ChemBioChem · doi:10.1002/cbic.201600491 · Cited by 28
Increased Expression of a MicroRNA Correlates with Anthelmintic Resistance in Parasitic Nematodes
Gillan, V., Maitland, K., Laing, R., Gu, H. Y., Marks, N. D., Winter, A. D., Bartley, D. J., Morrison, A. A., Skuce, P. J., Rezansoff, A., et al. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00452 · Cited by 32
“Non-coding RNAs are gaining prominence in other systems, both as drug targets and as mediators of resistance (Howe et al., 2015).”
BackgroundFrohlich, K. M., Weintraub, S. F., Bell, J. T., Todd, G. C., Väre, V. Y. P., Schneider, R. F., Kloos, Z. A., Tabe, E. S., Cantara, W. A., Stark, C. J., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201800744 · Cited by 28
Ribocentre-switch: a database of riboswitches
Bu, F., Lin, X., Liao, W., Lu, Z., He, Y., Luo, Y., Peng, X., Li, M., Huang, Y., Chen, X., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad891 · Cited by 30
“And then, 5FDQD, ribocil and ribocil C were found to target the FMN riboswitch and inhibit gene expression (Figure 3 D) ( 16 ,55 ).”
BackgroundParallel Discovery Strategies Provide a Basis for Riboswitch Ligand Design
Tran, B., Pichling, P., Tenney, L., Connelly, C. M., Moon, M. H., Ferré-D’Amaré, A. R., Schneekloth, J. S., & Jones, C. P. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.021 · Cited by 27
“, 2018), flavin mononucleotide (Blount et al., 2015; Howe et al., 2015; Lee et al., 2009; Motika et al., 2020), and lysine (Ataide et al.”
BackgroundThe promise of endogenous and exogenous riboflavin in anti-infection
Lei, J., Xin, C., Xiao, W., Chen, W., & Song, Z. (2021) · Virulence · doi:10.1080/21505594.2021.1963909 · Cited by 27
“Riboflavin is formed by GTP and Ru5P, and key enzymes are in red (reproduced from reference [37]).”
BackgroundTargeting RNA with small molecules, from RNA structures to precision medicines: IUPHAR review: 40
Tong, Y., Childs‐Disney, J. L., & Disney, M. D. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17308 · Cited by 28
“Ribocil is from phenotypic screening, its MoA has been well established by both resistance mutations, which validates its RNA target, and by co-crystallization of the Ribocil-riboswitch complex, which provides structural basis for its MoA (Balibar et al., 2018; Howe et al., 2015).”
DrugPred_RNA—A Tool for Structure-Based Druggability Predictions for RNA Binding Sites
Rekand, I. H., & Brenk, R. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00155 · Cited by 29
Frener, M., & Micura, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b11876 · Cited by 24
Predicting Positions of Bridging Water Molecules in Nucleic Acid–Ligand Complexes
Wei, W., Luo, J., Waldispühl, J., & Moitessier, N. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00163 · Cited by 27
Ligand Binding Mechanism and Its Relationship with Conformational Changes in Adenine Riboswitch
Hu, G., Li, H., Xu, S., & Wang, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061926 · Cited by 28
“Extensive experimental data suggest that conformational dynamics plays an important role in ligand binding and recognition at multiple levels [23,24].”
BackgroundRNA–ligand interaction scoring via data perturbation and augmentation modeling
Ma, H., Gao, L., Jin, Y., Ma, J., Bai, Y., Liu, X., Bao, P., Liu, K., Xu, Z. Z., & Lu, Z. J. (2025) · Nature Computational Science · doi:10.1038/s43588-025-00820-x · Cited by 25
Flipping the script: Understanding riboswitches from an alternative perspective
Olenginski, L. T., Spradlin, S., & Batey, R. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105730 · Cited by 28
“Given that riboswitches are becoming increasingly appreciated as therapeutic targets (182 – 186), a mechanism-based perspective of riboswitches, inclusive with respect to genetic regulation, will widen the scope for design and discovery of RNA-targeting small molecules.”
BackgroundDirect modulation of T-box riboswitch-controlled transcription by protein synthesis inhibitors
Stamatopoulou, V., Apostolidi, M., Li, S., Lamprinou, K., Papakyriakou, A., Zhang, J., & Stathopoulos, C. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx663 · Cited by 23
“Moreover, the recent discovery of ribocil, a synthetic mimic of the flavin mononucleotide, represents an innovative strategy to target specific bacterial riboswitches (10).”
BackgroundAtilho, R. M., Perkins, K. R., & Breaker, R. R. (2018) · RNA · doi:10.1261/rna.067975.118 · Cited by 23
“Previous work has determined that it is possible to design synthetic analogs that trick riboswitch classes into altering gene expression (Kim et al. 2009; Blount et al. 2015; Howe et al. 2015).”
BackgroundMammalian RNA switches: Molecular rheostats in gene regulation, disease, and medicine
Subbaiah, K. C. V., Hedaya, O. M., Wu, J., Jiang, F., & Yao, P. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.10.001 · Cited by 26
“Metabolite analogs and small chemical compounds have been screened as possible inhibitors of bacterial riboswitches, to assess their potential as candidates for the development of antibiotics [117,118].”
BackgroundSelf-citationStructure-based insights into recognition and regulation of SAM-sensing riboswitches
Zheng, L., Song, Q., Xu, X., Shen, X. R., Li, C., Li, H., Chen, H., & Ren, A. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2188-7 · Cited by 22
“Is this regard, a compound termed Ribocil was discovered to target FMN riboswitch and successfully suppress bacterial growth (Howe et al., 2015).”
BackgroundViral RNA Targets and Their Small Molecule Ligands
Hermann, T. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_20 · Cited by 24
“Just recently, a novel class of synthetic antibacterial compounds has been discovered, which exert their activity through an unprecedented mechanism of action that involves targeting a bacterial riboswitch involved in cofactor metabolism [111].”
BackgroundFluoro‐Carba‐Sugars are Glycomimetic Activators of the glmS Ribozyme
Matzner, D., Schüller, A., Seitz, T., Wittmann, V., & Mayer, G. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201702371 · Cited by 23
Pourmehran, Y., Sadri, F., Hosseini, S. F., Mohammadi, Y., & Rezaei, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117390 · Cited by 24
Neuner, E., Frener, M., Lusser, A., & Micura, R. (2018) · RNA Biology · doi:10.1080/15476286.2018.1534526 · Cited by 21
“The most prominent investigation employed a phenotypic screen and identified ribocil that acts as a structurally distinct mimic of the natural ligand flavin mononucleotide to repress ribB gene expression and inhibit cell growth [7].”
BackgroundSu, Y. A., Hu, J., Wang, Y., Li, Y., Xiao, L., He, X., Zhang, Z., Cai, J., Pan, D., Chen, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302659 · Cited by 21
Self-citationAntibacterial and antivirulence effect of 6-N-hydroxylaminopurine inListeria monocytogenes
Krajewski, S. S., Isoz, I., & Johansson, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1308 · Cited by 22
Computational approaches in design of nucleic acid-based therapeutics
Sherman, M. W., & Contreras, L. M. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.12.001 · Cited by 20
Synthetic Biology of Small RNAs and Riboswitches
Villa, J. K., Su, Y., Contreras, L. M., & Hammond, M. C. (2018) · ASM Press eBooks · doi:10.1128/9781683670247.ch31 · Cited by 20
Shedding light on the base-pair opening dynamics of nucleic acids in living human cells
Yamaoki, Y., Nagata, T., Kondo, K., Sakamoto, T., Takami, S., & Katahira, M. (2022) · Nature Communications · doi:10.1038/s41467-022-34822-4 · Cited by 19
Zsidó, B. Z., Bayarsaikhan, B., Börzsei, R., Szél, V., Mohos, V., & Hetényi, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411784 · Cited by 22
Progress toward the development of the small molecule equivalent of small interfering RNA
Disney, M. D., Suresh, B. M., Benhamou, R. I., & Childs‐Disney, J. L. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.01.001 · Cited by 19
Brodyagin, N., Hnedzko, D., MacKay, J. A., & Rozners, E. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0243-0_9 · Cited by 20
RNA‐mediated signal perception in pathogenic bacteria
Ignatov, D., & Johansson, J. (2017) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1429 · Cited by 20
“These data suggest that the bactericidal effect of ribocil is mediated primarily by targeting the FMN riboswitch, and ribocil is potentially safer for humans than the compounds affecting flavoenzymes.(127) 6-N-hydroxylaminopurine (6-N-HAP) is a guanine analog that binds guanine riboswitches and inhibits growth of B.”
BackgroundÜber bisherige Denkweisen hinaus – neue Wirkstoffe zur Überwindung der Antibiotika‐Krise
Lakemeyer, M., Zhao, W., Mandl, F. A. M., Hammann, P., & Sieber, S. A. (2018) · Angewandte Chemie · doi:10.1002/ange.201804971 · Cited by 19
Synthesis and evaluation of antimycobacterial activity of riboflavin derivatives
Harale, B., Kidwai, S., Ojha, D., Singh, M., Chouhan, D. K., Singh, R., Khedkar, V. M., & Rode, A. B. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128236 · Cited by 18
Enzymes in riboflavin biosynthesis: Potential antibiotic drug targets
Jaroensuk, J., Chuaboon, L., Kesornpun, C., & Chaiyen, P. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109762 · Cited by 19
Ligand Design for Riboswitches, an Emerging Target Class for Novel Antibiotics
Rekand, I. H., & Brenk, R. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0063 · Cited by 19
Design of RNA-targeting macrocyclic peptides
Walker, M. J. P., & Varani, G. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.04.029 · Cited by 23
Matyjasik, M. M., Hall, S. D., & Batey, R. (2020) · Molecules · doi:10.3390/molecules25102295 · Cited by 18
“While high-throughput phenotypic screens that have been used to find compounds with antimicrobial properties that target riboswitches have been successfully implemented [47,48], many compounds with favorable pharmacodynamics but unfavorable pharmacokinetics will have failed to be observed.”
BackgroundSynthetic RNA Modulators in Drug Discovery
Zamani, F., & Suzuki, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00154 · Cited by 20
Probing the Structures of Viral RNA Regulatory Elements with SHAPE and Related Methodologies
Rausch, J. W., Sztuba-Solińska, J., & Grice, S. F. J. L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02634 · Cited by 18
“…by the discovery of ligands capable of stimulating exon skipping (Luo and Disney, 2014) and others directed against a bacterial riboswitch (Howe et al., 2015), micro RNA (miRNA) linked to hepatocellular carcinoma (Childs-Disney and Disney, 2016) and RNA repeats associated with…”
BackgroundRestoration of Ribozyme Tertiary Contact and Function by Using a Molecular Glue for RNA
Dohno, C., Kimura, M., & Nakatani, K. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709041 · Cited by 17
Pavlova, N., Traykovska, M., & Prof. Robert Penchovsky, D. R. N. (2023) · Antibiotics · doi:10.3390/antibiotics12111607 · Cited by 17
A Machine Learning Method for RNA–Small Molecule Binding Preference Prediction
Chen, Z., Gao, J., Li, A., Liu, X., & Zhao, Y. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01324 · Cited by 17
Metadata
- Authors
- Howe, J. A., Wang, H., Fischmann, T. O., Balibar, C. J., Xiao, L., Galgoci, A. M., Malinverni, J. C., Mayhood, T., Villafania, A., Nahvi, A., Murgolo, N., Barbieri, C. M., Mann, P. A., Carr, D., Xia, E., Zuck, P., Riley, D., Painter, R. E., Walker, S. S., Sherborne, B., de Jesus, R., Pan, W., Plotkin, M. A., Wu, J., Rindgen, D., Cummings, J., Garlisi, C. G., Zhang, R., Sheth, P. R., Gill, C. J., Tang, H., & Roemer, T.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Roemer, Terry
- ORCID
- Venue
- Nature
- Published
- 2015-09-30
- Volume
- 526
- Issue
- 7575
- Pages
- 672-677
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1931081986
- Cited by
- 407
- References
- 55
- Citations by year
- 2026: 15 · 2025: 40 · 2024: 43 · 2023: 34 · 2022: 38 · 2021: 35 · 2020: 39 · 2019: 43 · 2018: 42 · 2017: 40 · 2016: 35 · 2015: 2
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Institute of Microbiology, Chinese Academy of Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- riboswitches, flavin mononucleotide, non-coding RNA, riboflavin biosynthesis, antibiotic discovery, phenotypic screening
- MeSH terms
- Animals, Bacteria, Base Sequence, Escherichia coli Infections, Female, Flavin Mononucleotide, Heat-Shock Proteins, Ligands, Mice, Inbred DBA, Models, Molecular, Molecular Sequence Data, Pyrimidines, Riboflavin, RNA, Bacterial, Substrate Specificity, Reproducibility of Results, Gene Expression Regulation, Bacterial, Crystallography, X-Ray, Intramolecular Transferases, Escherichia coli Proteins, Mice, Aptamers, Nucleotide, Riboswitch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.